NCT03051217

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: UCB Biopharma S.P.R.L. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.

Conditions

• Moderate to Severe Psoriasis
• Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Interventions

Type	Name	Description
OTHER	Placebo	* Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 0.9 % saline * Route of Administration: Subcutaneous use Q2W
DRUG	Certolizumab Pegol	* Pharmaceutical Form: Solution for injection in pre-filled syringe * Concentration: 200 mg/mL * Route of Administration: Subcutaneous use

Timeline

• Start date: 2017-02-21
• Primary completion: 2018-11-19
• Completion: 2019-01-16
• First posted: 2017-02-13
• Last updated: 2022-01-04
• Results posted: 2019-12-11

Locations

33 sites across 1 country: Japan